Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Rejects Novartis’ Xolair In Harbinger Of Cost Reevaluation Process

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft guidance from NICE concludes that Novartis’ asthma drug Xolair, which was previously viewed as cost-effective, is no longer worth the expense based on new independent economic modeling and mortality data. The re-evaluation process is spreading through Europe as governments move to restrain costs, and that may spell trouble for manufacturers.

You may also be interested in...

Xolair’s Price Discount For NICE Is Ominous Sign For Older Products

Novartis essentially makes volume trade-off in the most recent NICE assessment, adding a claim for ages 6-11 but offering pricing concessions as well; if the firm’s experience is any indication, even older products that come under NICE’s cost-effectiveness scrutiny will need discounts and additional data to stay in the authority’s good graces.

NICE Rejects Novartis’ Xolair Use In Younger Children

NICE’s analysis found that omalizumab was only useful in reducing the rate of clinically significant exacerbations in children with asthma who were having three of more exacerbations per year.

MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts